Opinion

Video

Exploring Key Insights from the PAPILLON Trial

A clinical pharmacy specialist examines treatment strategies for EGFR exon 20 insertion mutations, referencing data from the PAPILLON trial, and addresses the challenges associated with managing brain metastases in this patient population.

  1. Amivantamab (used with or without chemotherapy, depending on the treatment stage) stands out as the sole recommended treatment for EGFR exon 20 insertion mutations. Its front-line use is supported by the PAPILLON study. What was this study’s methodology?
  2. What were the key results of PAPILLON in terms of both efficacy and safety?
  3. How do you navigate treatment decisions for EGFR-mutated NSCLC patients with brain metastases, considering CNS penetration of the various EGFR-targeted therapies?
Related Videos
3 KOLs are featured in this series.
3 KOLs are featured in this series.
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
3 KOLs are featured in this series.
3 KOLs are featured in this series.
WCLC, lung cancer, NSCLC
MARIPOSA Study: Long-Term Outcomes and Next Steps for Amivantamab Plus Lazertinib in EGFR-Mutant NSCLC
The EMPOWER-Lung 1 Trial: Five-Year Outcomes of Cemiplimab Monotherapy in Advanced NSCLC
3 KOLs are featured in this series.
Related Content
Solid tumor -- Image credit: Yuriy | stock.adobe.com
October 22nd 2024

Introducing Tarlatamab-dlle: A New Era in Oncology Treatment

Amir Ali, PharmD, BCOP Phoebe Kim, PharmD Candidate Stacey Cheung, PharmD Candidate Samantha Shi, PharmD, BCOP Harry Shamamian, PharmD, MBA, FACHE Hien Tang, PharmD, BCOP
Pharmacy Focus: Oncology Edition- Benefits of Subcutaneous Amivantamab for Lung Cancer Treatment
June 27th 2024

Pharmacy Focus: Oncology Edition- Benefits of Subcutaneous Amivantamab for Lung Cancer Treatment

FDA Approval Seal -- Image credit: B-design | stock.adobe.com
October 4th 2024

FDA Approves Nivolumab for the Treatment of Adult Patients With Resectable NSCLC

Gillian McGovern, Assistant Editor
Pharmacy Focus: Oncology Edition- Latest Updates in Non-Small Cell Lung Cancer Treatment
February 26th 2024

Pharmacy Focus: Oncology Edition- Latest Updates in Non-Small Cell Lung Cancer Treatment

Image Credit: © Postmodern Studio - stock.adobe.com
Published: September 26th 2024 | Updated: September 26th 2024

FDA Approves Osimertinib for Unresectable EGFR-Mutated Lung Cancer

Alexandra Gerlach, Associate Editor
FDA Approves Amivantamab-vmjw for NSCLC With EGFR Exon 19 Deletions or L858R Mutations
September 20th 2024

FDA Approves Amivantamab-vmjw for NSCLC With EGFR Exon 19 Deletions or L858R Mutations

Aislinn Antrim, Assistant Managing Editor